Searchable abstracts of presentations at key conferences in endocrinology

ea0044oc5.6 | Diabetes Mellitus and Metabolism | SFEBES2016

IRX3 regulates Adipocyte Browning via Mitochondrial Gene Clusters

Laber Samantha , Agnew Thomas , Cox Roger

Genome-wide association studies have repeatedly shown that the strongest association with human BMI is arising from variants in the first intron of Fto. It has recently been demonstrated that intronic Fto variants are within an adipocyte-specific enhancer and that risk allele carriers have altered Irx3 and Irx5 expression in early adipogenesis (Claussnitzer et al. NEJM 2015). The aim of our study is to investigate the functional role of Irx3 in adipocytes. We show that silenci...

ea0044p63 | Clinical biochemistry | SFEBES2016

Pheochromocytoma and Paraganglioma audit

Ravindran Ravikumar , Dacruz Thomas , Rees Aled

Aim: To assess whether using urine catecholamines as a second line investigation has affected clinical decision making in patients with suspected pheochromocytoma and paraganglioma.The need for the audit: New society of endocrine guidelines in June 14, have recommended using urine metanephrines as the initial screening test for PPGL. Current practise at University Hospital Wales is to offer urine catecholamines as the second line test to patients with a ...

ea0044p97 | Diabetes and Cardiovascular | SFEBES2016

SGLT2 inhibitors: results from clinical practice

Border Daniel K. , Barber Thomas M.

Introduction: There is growing real-world experience of the SGLT2 inhibitor class for type 2 diabetes mellitus (T2D). We performed an audit of clinico-biochemical effects of SGLT2 inhibitor use for patients with diabesity in the context of a tier-3 obesity service within a UK-based teaching hospital.Methods: We included patients with a confirmed diagnosis of T2D who had been treated with an SGLT2 inhibitor within licensed indications (monotherapy and add...

ea0044p178 | Obesity and Metabolism | SFEBES2016

Dramatic weight loss induced by dapagliflozin and tier 3 obesity service support

Border Daniel K , Barber Thomas M

The importance of weight reduction in the management of diabesity is well-established. However, significant weight loss can be difficult to achieve without bariatric surgery, even within specialist tier 3 obesity services. Here we describe the case of a 52 year old man who presented to weight management clinic. He had made multiple weight loss attempts, but with little success. On presentation, his weight was 140.8 kg with a BMI of 40.3 kg/m2, and he had now been static at thi...

ea0041ep327 | Clinical case reports - Thyroid/Others | ECE2016

A rare case of infertility – SRY positive, 46,XX testicular disorder of sexual differentiation

Bogdanet Delia , Griffin Thomas , Bell Marcia

Introduction: The testicular disorder of sexual differentiation (DSD) is a rare clinical condition with a reported incidence of 1:20 000 newborn males. It is characterised by a male phenotype with 46,XX karyotype. There are three clinical phenotypes: normal male phenotype, males with genital ambiguities and males who are true hermaphrodites. SRY positive 46,XX testicular DSD results from the translocation of a Y chromosome segment containing the SRY gene during spermatogenesis...

ea0041ep1000 | Thyroid (non-cancer) | ECE2016

Autoimmune thyroid diseases (AITD) and mental illness: An evaluation of parietal cell antibodies, intrinsic factor antibodies, vitamin B12 and psychiatric symptoms in patients with AITD and Non-AITD controls

Leineweber Doerte , Galling Britta , Schurmeyer Thomas H.

Introduction: Associations of autoimmune thyroid disease (AITD) with autoimmune gastri-tis and mental disorders have been suggested, but evidence for a connection is lacking.Methods: We compared the co-incidence of parietal cell antibodies (PCA>20 RE/ml), intrinsic factor antibodies (IFA>1.19 AU/ml), vitamin B12 plasma levels (<200 pg/ml) and mental illness in patients with AITD (n=398), e.g. active (TPO+), atrophic (TPO−) and ...

ea0038p346 | Pituitary | SFEBES2015

Silent corticotroph adenoma presenting with severe visual loss

Rich Laura , Thomas Julia , Grieve Joan

A 51-year-old man presented to an optometrist with a 3-week history of visual impairment following a minor headache. He was found to have reduced visual acuity 6/24 in both eyes and a dense bitemporal hemianopia and was referred urgently to Musgrove Park Emergency Department. MRI brain showed a cystic bleed from a pituitary macroadenoma, 30 mm in diameter, with compression of the optic chiasm. He had no clinical features of Cushing’s or other hormone excess or deficiency ...

ea0038p488 | Thyroid | SFEBES2015

Hypercalcaemia: look beyond the usual

Rahman Mohammad M , Hickin Thomas R

We present a case of a 50 year old patient with sepsis and a significant and symptomatic hypercalcaemia of 3.38 mmol/l with a background of MS. The infection responded to treatment however the hypercalcaemia persisted despite appropriate measures. Further investigation showed a suppressed PTH, normal ACE level, electrophoresis and 25(OH) vitamin D level, but found her to be thyrotoxic with TSH suppressed at <0.01, free T4 – 37.2 nmol/l, free T3 – 212 nmol/l. She ...

ea0037gp.09.03 | Nuclear receptors and signalling | ECE2015

Agonist-selective phosphorylation of the human sst3 somatostatin receptor determined by phosphosite-specific antibodies

Lehmann Andreas , Schulz Stefan , Gunther Thomas

The human somatostatin receptor 3 (hsst3) is expressed in about 50% of all neuroendocrine tumours. The sst3 receptor is unique among somatostatin receptors which can initiate apoptosis of tumour cells through activation of the tumour suppressor p53. Furthermore, treatment of the sst3 receptor with somatostatin or stable somatostatin analogues such as octreotide or pasireotide can inhibited tumour cell proliferation. However, at present little is known about the agonist-induced...

ea0033oc4.3 | Oral Communications 4 | BSPED2013

The incentive trial: do financial rewards improve glycaemic control in teenagers with poorly controlled type 1 diabetes?

Frerichs Carley , Thomas Douglas , Randell Tabitha

Introduction: Adolescence is recognised as a period where compliance to diabetes treatment is challenging and adolescents assume increasing responsibility for their diabetes self-management. In this study we investigated whether giving modest financial rewards motivated teenagers with type 1 diabetes to improve glycaemic control.Methods: Population; young people with type 1 diabetes, age 13–16 years at entry, duration of diabetes of >2 years and...